Tango Therapeutics, Inc. (TNGX): who owns it and who trades it
As of Nov 16, 2026, TNGX insiders reported 30 open-market sales worth $8.1M and no purchases in the last 12 months, with 13% of the sale value made under pre-set 10b5-1 plans. The largest seller was Adam Crystal (President), with $7.2M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Tango Therapeutics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TNGX
246 funds and institutions reported TNGX shares worth $6.8B at the end of Q2 2026. The largest holder is Rtw Investments, LP with $435M.
10 largest owners, by value
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Rtw Investments, LP | 13.90M | – | $435M | +5% |
| BlackRock, Inc. | 12.44M | – | $389M | +42% |
| FMR LLC (Fidelity) | 12.33M | – | $386M | +25% |
| Farallon Capital Management, L.l.c. | 12.28M | – | $384M | +35% |
| Boxer Capital Management, LLC | 10.88M | – | $340M | No change |
| Goldman Sachs Group Inc | 9.98M | – | $312M | +97% |
| TCG Crossover Management, LLC | 9.08M | – | $284M | -14% |
| Trv Gp Iv, LLC | 6.37M | – | $120M | No change |
| Paradigm Biocapital Advisors LP | 6.36M | – | $199M | +59% |
| T. Rowe Price Associates | 6.35M | – | $198M | +614% |
| Siren, L.L.C. | 6.18M | – | $193M | +9% |
| State Street Corp | 5.98M | – | $187M | +29% |
| Vanguard Capital Management LLC | 5.96M | – | $186M | +15% |
| Adage Capital Partners Gp, L.l.c. | 5.60M | – | $175M | -56% |
| Jupiter Topco LLC | 5.06M | – | $158M | – |
| Deep Track Capital, LP | 4.20M | – | $131M | +53% |
| Deerfield Management Company, L.P. | 4.19M | – | $131M | +1% |
| Woodline Partners LP | 4.00M | – | $125M | -50% |
| Geode Capital Management, LLC | 3.74M | – | $117M | +40% |
| Perceptive Advisors LLC | 3.38M | – | $106M | +318% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TNGX insiders reported $0 of open-market purchases and $8.1M of sales. 13% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 11, 2026 | Adam Crystal | President | Sale plan | 5,000 | $25.00 | $125K | Form 4 |
| Nov 2, 2026 | Adam Crystal | President | Sale plan | 3,900 | $22.26 | $86.8K | Form 4 |
| Nov 2, 2026 | Adam Crystal | President | Sale plan | 1,100 | $22.99 | $25.3K | Form 4 |
| Nov 2, 2026 | Jessica Newcomb | Principal Accounting Off | Sale plan | 5,571 | $22.28 | $124K | Form 4 |
| Nov 2, 2026 | Jessica Newcomb | Principal Accounting Off | Sale plan | 1,460 | $22.98 | $33.6K | Form 4 |
| Oct 1, 2026 | Adam Crystal | President | Sale plan | 26,400 | $24.45 | $646K | Form 4 |
| Oct 1, 2026 | Adam Crystal | President | Sale plan | 600 | $25.32 | $15.2K | Form 4 |
| Sep 22, 2026 | Jessica Newcomb | Principal Accounting Off | Sale | 2,400 | $25.17 | $60.4K | Form 4 |
| Sep 22, 2026 | Jessica Newcomb | Principal Accounting Off | Sale | 5,100 | $23.97 | $122K | Form 4 |
| Sep 22, 2026 | Jessica Newcomb | Principal Accounting Off | Sale | 700 | $22.80 | $16K | Form 4 |
| Sep 1, 2026 | Adam Crystal | President | Sale | 27,000 | $22.37 | $604K | Form 4 |
| Aug 3, 2026 | Adam Crystal | President | Sale | 21,733 | $27.35 | $594K | Form 4 |
| Aug 3, 2026 | Adam Crystal | President | Sale | 5,267 | $26.79 | $141K | Form 4 |
| Jul 1, 2026 | Adam Crystal | President | Sale | 7,371 | $30.25 | $223K | Form 4 |
| Jul 1, 2026 | Adam Crystal | President | Sale | 19,629 | $29.34 | $576K | Form 4 |
| Jun 1, 2026 | Adam Crystal | President | Sale | 20,860 | $23.06 | $481K | Form 4 |
| Jun 1, 2026 | Adam Crystal | President | Sale | 6,140 | $22.25 | $137K | Form 4 |
| May 1, 2026 | Adam Crystal | President | Sale | 25,900 | $21.19 | $549K | Form 4 |
| May 1, 2026 | Adam Crystal | President | Sale | 1,100 | $22.00 | $24.2K | Form 4 |
| Apr 15, 2026 | Adam Crystal | President | Sale | 38,460 | $25.00 | $962K | Form 4 |
| Apr 1, 2026 | Adam Crystal | President | Sale | 27,000 | $21.20 | $572K | Form 4 |
| Mar 25, 2026 | Adam Crystal | President | Sale | 12,000 | $20.11 | $241K | Form 4 |
| Mar 5, 2026 | Adam Crystal | President | Sale | 20,251 | $15.00 | $304K | Form 4 |
| Feb 25, 2026 | Adam Crystal | President | Sale | 54,345 | $12.77 | $694K | Form 4 |
| Feb 3, 2026 | Daniella Beckman | CFO | Sale | 10,204 | $12.26 | $125K | Form 4 |
| Feb 3, 2026 | Daniella Beckman | CFO | Sale | 113 | $12.90 | $1.5K | Form 4 |
| Feb 3, 2026 | Barbara Weber | Chair | Sale | 333 | $12.90 | $4.3K | Form 4 |
| Feb 3, 2026 | Barbara Weber | Chair | Sale | 30,186 | $12.26 | $370K | Form 4 |
| Feb 3, 2026 | Adam Crystal | President | Sale | 201 | $12.90 | $2.6K | Form 4 |
| Feb 3, 2026 | Adam Crystal | President | Sale | 18,251 | $12.26 | $224K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Adam Crystal | President, R&D | – | $7.2M | Nov 11, 2026 |
| Barbara Weber | Director, Executive Chair, Director | – | $374K | Feb 3, 2026 |
| Jessica Newcomb | Principal Accounting Officer | – | $356K | Nov 2, 2026 |
| Daniella Beckman | Chief Financial Officer | – | $127K | Feb 3, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TNGX short interest
Very high short interest. 28.6% of TNGX shares are sold short: about 1 share in 3. Over the last 12 reports the number of shares short went up 52%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 48.24M TNGX shares were sold short, 28.6% of the shares outstanding, up 7.7% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 9.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 48.24M | 28.61% | +8% | 4.96M | 9.7 |
| Oct 15, 2026 | 44.78M | 26.56% | +1% | 4.01M | 11.2 |
| Sep 30, 2026 | 44.50M | 26.39% | +6% | 3.55M | 12.5 |
| Sep 15, 2026 | 41.87M | 24.83% | -2% | 2.23M | 18.8 |
| Aug 31, 2026 | 42.63M | 25.28% | -1% | 2.16M | 19.7 |
| Aug 14, 2026 | 43.19M | 25.61% | -3% | 2.06M | 20.9 |
| Jul 31, 2026 | 44.61M | 31.26% | +4% | 2.33M | 19.1 |
| Jul 15, 2026 | 42.72M | 29.94% | +2% | 2.79M | 15.3 |
| Jun 30, 2026 | 42.01M | 29.44% | +23% | 6.38M | 6.6 |
| Jun 15, 2026 | 34.04M | 23.86% | +2% | 6.27M | 5.4 |
| May 29, 2026 | 33.49M | 23.47% | +5% | 2.57M | 13.0 |
| May 15, 2026 | 31.81M | 22.29% | -17% | 3.18M | 10.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Tango Therapeutics company events
Tango Therapeutics filed 17 reports on Form 8-K in the last 12 months, 8 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 23, 2026AnnouncementThe Company disclosed promising results from its ongoing Phase 1/2 trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer. Filing
- Aug 11, 2026AnnouncementAs previously disclosed, on November 21, 2025, Tango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Aug 7, 2026LeadershipAmended an earlier report. Of the Original Form 8-K to include the terms of the executed separation agreement. Filing
- Aug 6, 2026LeadershipDr. Barbara Weber’s employment with Tango Therapeutics, Inc. as its Executive Chair ended on August 3, 2026 in accordance with the terms of her Amended and Restated Employment Agreement dated January 8, 2026. Filing
- Jun 23, 2026LeadershipThe Board of Directors of Tango Therapeutics, Inc. increased the number of directors of the Company to seven (7). Filing
- Jun 10, 2026AgreementTango Therapeutics, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and Leerink Partners LLC as representatives to the several underwriters named in the Underwriting Agreement, relating to an underwritten offering of (i) 18,166,667 shares of the Company’s common stock… Filing
- Jun 8, 2026AnnouncementThe Company disclosed initial safety and efficacy data from its Phase 1/2 combination trial evaluating vopimetostat in combination with RAS(ON) inhibitors from Revolution Medicines, Inc. in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma. Filing
- Jun 4, 2026VoteReported shareholder vote results. Filing
- May 13, 2026LeadershipAlexis Borisy resigned from the Company’s Board of Directors, as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board and as a member thereof, in each case effective as of May 13, 2026. Filing
- May 8, 2026LeadershipSeparation Agreement As previously announced, on April 10, 2026, the board of directors of Tango Therapeutics, Inc. determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15… Filing
- Apr 15, 2026LeadershipThe board of directors of Tango Therapeutics, Inc. determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 8, 2026LeadershipBarbara Weber, M.D. notified the board of directors of the Company of her retirement and resignation as President and Chief Executive Officer of the Company, in each case, effective as of January 8, 2026. Filing
- Jan 5, 2026LeadershipThe Board of Directors of Tango Therapeutics, Inc. increased the number of directors of the Company to eight (8). Filing
- Nov 21, 2025AgreementTango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC, pursuant to which the Company may sell, from time to time, at its option, shares of the Company’s common stock, $0.001 par value per share, through the Agent, as sales agent. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Tango Therapeutics financials
Famous investors that hold TNGX
5 of the 50 well-known investors we track reported holding TNGX in their latest 13F filing. The largest position is Ken Fisher's, worth $26.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Fisher · Fisher Asset Management | Q3 2026 | 1.07M | $26.7M | 0.0% | +85% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 445,367 | $11.1M | 0.0% | +146% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 389,857 | $9.7M | 0.0% | -48% |
| Israel Englander · Millennium Management | Q3 2026 | 381,372 | $9.5M | 0.0% | -23% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 86,220 | $2.2M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named TNGX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Farallon Capital Management, L.L.C. | 13G/A | 4.9% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 4.6% |
| Nov 16, 2026 | Farallon Capital Management, L.L.C. | 13G/A | 4.9% |
| Nov 16, 2026 | TCG Crossover GP II, LLC | 13G/A | 4.6% |
| Nov 6, 2026 | FMR LLC | 13G/A | 15.0% |
| Nov 6, 2026 | FMR LLC | 13G/A | 15.0% |
Questions about Tango Therapeutics, Inc. (TNGX) stock
Who owns the most TNGX stock?
The largest reported owner of Tango Therapeutics, Inc. (TNGX) is Rtw Investments, LP. In total, 246 funds and institutions reported holding TNGX at the end of Q2 2026. See the largest owners.
Are TNGX insiders buying or selling?
In the last 12 months, TNGX insiders reported no open-market purchases and 30 sales worth $8.1M. The latest trade was on Nov 11, 2026. See every trade.
What is the short interest in TNGX?
As of Oct 30, 2026, 48.24M TNGX shares were sold short, 28.6% of the shares outstanding, up 7.7% from the report before. At the average daily volume of 4.96M shares, buying them all back would take about 9.7 trading days (days to cover). See the history.
Which famous investors hold TNGX?
5 of the 50 well-known investors we track reported TNGX in their latest 13F filing, including Ken Fisher, Ken Griffin, Jim Simons. The largest position is worth $26.7M. See all holders.
Executive pay
Tango Therapeutics's chief executive was paid a total of $2.8M for the year ended Dec 31, 2025, down 57% from $6.5M the year before. In the last 12 months, Tango Therapeutics's executives and directors bought no stock on the open market and sold $8.1M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.